Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer
Authors
Keywords
Metastatic pancreas cancer, Chemotherapy costs, Value, Toxicity costs, First-line regimens
Journal
MEDICAL ONCOLOGY
Volume 33, Issue 5, Pages -
Publisher
Springer Nature
Online
2016-04-14
DOI
10.1007/s12032-016-0762-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)
- (2015) N. I. Cherny et al. ANNALS OF ONCOLOGY
- Cancer statistics, 2015
- (2015) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Can Money Really Be No Object When Cancer Care Is the Subject?
- (2015) Leonard B. Saltz JOURNAL OF CLINICAL ONCOLOGY
- First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States–Based Cost-Effectiveness Analysis
- (2015) Daniel A. Goldstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally Recurrent or Metastatic Breast Cancer: CALGB 40502/NCCTG N063H (Alliance)
- (2015) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- Modified gemcitabine and nab-paclitaxel in patients with metastatic pancreatic cancer (MPC): A single-institution experience.
- (2015) Kavya Krishna et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options
- (2015) Lowell E. Schnipper et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer
- (2014) C.L. Attard et al. Current Oncology
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings
- (2010) M Okera et al. BRITISH JOURNAL OF CANCER
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
- (2009) Michael Drummond et al. VALUE IN HEALTH
- An Empiric Estimate of the Value of Life: Updating the Renal Dialysis Cost-Effectiveness Standard
- (2008) Chris P. Lee et al. VALUE IN HEALTH
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started